Abcam Founder Launches Grab for Votes to Block $5.7 Billion Deal

Corporate America Brings Its New Skinny Look to Stock Market

Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep

Catalent Cuts Annual Forecast More Than Expected, Delays Earnings Report Again

Drug Contractor Catalent Plunges After Annual Guidance Cut, Results Delayed